The metabolic syndrome and chronic liver disease
- PMID: 24320032
- DOI: 10.2174/1381612819666131206111352
The metabolic syndrome and chronic liver disease
Abstract
The prevalence of the metabolic syndrome (MetS), a cluster of cardiovascular risk factors associated with obesity and insulin resistance, is dramatically increasing in Western and developing countries. This disorder is not only associated with a higher risk of appearance of type 2 diabetes and cardiovascular events, but impacts on the liver in different ways. Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of MetS, and is characterized by triglyceride accumulation and a variable degree of hepatic injury, inflammation, and repair. In the presence of significant hepatocellular injury and inflammation, the picture is defined 'nonalcoholic steatohepatitis' (NASH), that has the potential to progress to advanced fibrosis and cirrhosis. Diagnosis of NASH is based on a liver biopsy, and active search for noninvasive tests is ongoing. Progression of steatohepatitis to advanced fibrosis or cirrhosis has been shown in at least one third of patients followed with paired biopsies. Presence of NASH is associated with lower life expectancy, both due to liver-related death and to an increase in cardiovascular events. The appearance of NAFLD is mainly dependent on increased flow of fatty acids derived from an excess of lipolysis from insulin-resistant adipose tissue. Development of NASH is based on lipotoxicity and is influenced by signals derived from outside the liver and from intrahepatic activation of inflammatory and fibrogenic pathways. The presence of the MetS is also associated with worse outcomes in patients with cirrhosis due to any causes, and has complex interactions with hepatitis C virus infection. Moreover, MetS poses a higher risk of development of hepatocellular carcinoma, not necessarily through the development of NASH-related cirrhosis. In conclusion, the presence of metabolic alterations has a severe and multifaceted impact on the liver, and is responsible for a higher risk of liver-dependent and -independent mortality.
Similar articles
-
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17. Indian J Med Res. 2019. PMID: 31115369 Free PMC article. Review.
-
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14. Am J Gastroenterol. 2017. PMID: 28195177
-
Nonalcoholic Steatohepatitis: A Review.JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298. JAMA. 2020. PMID: 32207804 Review.
-
[Advances in diagnosis and treatment of nonalcoholic fatty liver disease].Zhonghua Gan Zang Bing Za Zhi. 2016 Feb;24(2):81-4. doi: 10.3760/cma.j.issn.1007-3418.2016.02.001. Zhonghua Gan Zang Bing Za Zhi. 2016. PMID: 26983471 Chinese.
-
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.Atherosclerosis. 2014 Jan;232(1):99-109. doi: 10.1016/j.atherosclerosis.2013.10.030. Epub 2013 Nov 6. Atherosclerosis. 2014. PMID: 24401223 Review.
Cited by
-
Diagnostic imaging in the management of patients with metabolic syndrome.Transl Res. 2018 Apr;194:1-18. doi: 10.1016/j.trsl.2017.10.009. Epub 2017 Nov 22. Transl Res. 2018. PMID: 29175480 Free PMC article. Review.
-
Cellular Mechanisms of Liver Fibrosis.Front Pharmacol. 2021 May 6;12:671640. doi: 10.3389/fphar.2021.671640. eCollection 2021. Front Pharmacol. 2021. PMID: 34025430 Free PMC article. Review.
-
Association between Dietary Patterns and Serum Hepatic Enzyme Levels in Adults with Dyslipidemia and Impaired Fasting Plasma Glucose.Nutrients. 2021 Mar 18;13(3):987. doi: 10.3390/nu13030987. Nutrients. 2021. PMID: 33803758 Free PMC article.
-
The innate immune receptor TREM-1 promotes liver injury and fibrosis.J Clin Invest. 2018 Nov 1;128(11):4870-4883. doi: 10.1172/JCI98156. Epub 2018 Oct 2. J Clin Invest. 2018. PMID: 30137027 Free PMC article.
-
Interesterified Fats Induce Deleterious Effects on Adipose Tissue and Liver in LDLr-KO Mice.Nutrients. 2019 Feb 22;11(2):466. doi: 10.3390/nu11020466. Nutrients. 2019. PMID: 30813339 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical